Filing and business context
Issuer: IMARA Inc. (ticker IMRA), not Enliven Therapeutics, Inc. This is IMARA’s Form 10-K for the fiscal year ended December 31, 2020, filed March 5, 2021. The requested “2020 Q4” corresponds to the year-end period; this is an annual report, not a quarterly filing.
IMARA was a clinical-stage biopharmaceutical company with no approved products or product revenue. Its lead and sole clinical-stage candidate, oral PDE9 inhibitor IMR-687, was being developed for sickle cell disease (SCD) and beta-thalassemia. The company also reported preclinical work in heart failure with preserved ejection fraction (HFpEF).
Financial results and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $32.2 million | $19.0 million |
| General and administrative expense | $9.5 million | $5.1 million |
| Total operating expenses / operating loss | $41.7 million | $24.1 million |
| Net loss | $41.4 million | $23.5 million |
| Net loss per common share | $3.53 | $33.40 |
| Net cash used in operating activities | $37.4 million | $21.9 million |
Expenses rose substantially, principally from increased IMR-687 clinical development and manufacturing costs, added research and development personnel, and public-company costs. The 2020 loss attributable to common stockholders was $49.2 million, including $7.9 million of preferred-stock accretion; the reported net loss was $41.4 million.
At December 31, 2020, cash and cash equivalents were $47.7 million and short-term investments were $40.5 million, totaling $88.2 million. Current liabilities were $6.2 million and total liabilities were $6.4 million; the filing reports no debt balance. Management estimated that available cash, cash equivalents and investments would fund operating expenses and capital needs into mid-2022, subject to assumptions and operating-plan changes. The company stated it would need additional funding and had no committed external financing source.
Operating cash use was $37.4 million; investing cash use was $16.7 million, largely reflecting net investment purchases; financing provided $96.9 million, principally from the IPO and Series B preferred-stock financing. The March-April 2020 IPO generated approximately $76.5 million net proceeds, and the February 2020 preferred financing generated approximately $17.1 million net proceeds. The company had no off-balance-sheet arrangements. No operating margin is meaningful because there was no revenue.
Material changes and development progress
- Compared with 2019, 2020 net loss increased by about $17.9 million and operating cash use increased by about $15.5 million, as development spending expanded.
- IMARA completed its IPO in March 2020; all outstanding preferred stock converted into common stock. Common shares outstanding were 17,548,263 at year-end 2020.
- Phase 2b trials in SCD and beta-thalassemia began in the second quarter of 2020 and were enrolling. Management expected interim results from both in the second half of 2021.
- In January 2021, after the reporting year, IMARA disclosed Phase 2a SCD topline results: IMR-687 was reported as generally well tolerated, with a lower rate of vaso-occlusive/sickle-cell pain crises and related hospitalizations in a specified monotherapy subgroup than placebo. Biomarker changes varied by population; the filing describes the results as preliminary and notes additional analyses remained underway.
- Preliminary four-month data from approximately 12 evaluable open-label extension participants showed increases in HbF and F-cells, with minimal changes in total hemoglobin. The filing also describes favorable observations in two individual patient narratives, while cautioning that the cases are small and include retrospective comparisons.
Outlook, risks and unusual items
Management planned to continue the SCD and beta-thalassemia Phase 2b programs, pursue an SCD pediatric program and evaluate higher IMR-687 doses. It was developing a Phase 2 protocol for potential HFpEF clinical development, but provided no financial guidance or forecast of revenue or profitability. It expected significant losses and expenses to continue and stated profitability might never be achieved.
Key uncertainties include whether Phase 2 findings translate into meaningful clinical benefit; whether HbF or other biomarkers will be accepted by regulators as clinically meaningful or as a surrogate endpoint; and whether IMR-687 can progress through larger trials and obtain approval. The FDA had recommended a Phase 2b dose-finding approach and said further discussion would be needed on HbF as a potential surrogate. COVID-19 had caused missed or incomplete Phase 2a visits and delays to Phase 2b site activation, enrollment and regulatory review, with potential for further delays.
Other material risks include dependence on IMR-687, need for substantial additional capital, clinical and regulatory failure, competition, uncertain patient recruitment and reimbursement, and reliance on third-party manufacturers. The company relied on a single API manufacturer and a separate single finished-drug manufacturer. IMR-687 was licensed from Lundbeck; potential milestone payments total up to $23.5 million for licensed products, in addition to tiered royalties. No material legal proceedings were reported. The auditor issued an unqualified opinion on the financial statements; management reported disclosure controls were effective, but the 10-K did not include management’s internal-control assessment or auditor attestation under the newly public company transition relief.
Investor verification checklist
- Confirm issuer identity and ticker: this filing is IMARA Inc. (IMRA), not Enliven Therapeutics, Inc.
- Review audited financial statements and cash runway assumptions, including the mid-2022 estimate and expected financing needs.
- Track complete Phase 2b SCD and beta-thalassemia data, enrollment, safety, dose decisions and the impact of COVID-19 delays.
- Assess whether biomarker changes and subgroup/case observations are replicated and linked to clinically meaningful outcomes; distinguish preliminary findings from controlled trial conclusions.
- Review FDA feedback on HbF as a surrogate endpoint and the requirements and timing for pivotal trials or accelerated approval.
- Monitor financing and dilution risk, Lundbeck milestones and royalties, and manufacturing capacity and supplier concentration.